RecruitingType 2 Diabetes (Adult Onset)
Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes
Eligible age
18–75 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The primary purpose of this study is to evaluate the efficacy, durability, and mechanism of HbA1c reduction produced by the combination of pioglitazone plus tirzepatide compared to metformin plus sitagliptin in patients with recently diagnosed type 2 diabetes mellitus.
Sponsor: The University of Texas Health Science Center at San Antonio
You may qualify if…
- ✓ 1. Ability of subject to understand and the willingness to sign a written informed consent document.
- ✓ 2. Males and females; Age 18-75 years
- ✓ 3. Recently (within 5 years) diagnosed Type 2 Diabetes Mellitus (T2DM) patients
- ✓ 4. Drug naïve or receiving metformin monotherapy
- ✓ 5. HbA1c \>6.5% (no limit on upper HbA1c value);
- ✓ 6. Willingness to adhere to the investigational product regimen
- ✓ 7. Good general health
- ✓ 8. Stable body weight over the preceding 3 months
You may not qualify if…
- ✕ 1. positive anti-GAD (antibodies to glutamic acid decarboxylase)
- ✕ 2. pregnancy or plan of becoming pregnant
- ✕ 3. evidence of proliferative diabetic retinopathy,
- ✕ 4. plasma creatinine \>1.4 females or \>1.5 males;
- ✕ 5. presence of congestive heart failure (CHF);
- ✕ 6. history of cancer (\<5 years);
- ✕ 7. prior history of pancreatitis,
- ✕ 8. bladder cancer or family history of thyroid tumors;
Where it's recruiting
Texas
San Antonio
Source: ClinicalTrials.gov · NCT06246799 · last updated 2026-03-10